Drug intelligence / Profile preview

CKD-390

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

CKD-390 is an investigational pharmaceutical drug currently in clinical development. It is being evaluated in a multicenter, randomized, double-blind, parallel-design Phase III clinical trial to assess its efficacy and safety as a tablet formulation. The specific mechanism of action, molecular target(s), and primary indication are not detailed in the available sources; however, the context suggests it is intended for use in chronic kidney disease or related conditions[1]. Further details regarding its pharmacological class or precise therapeutic application remain undisclosed.

Beyond the preview

Go deeper on CKD-390.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-390.

Explore the full profile